Order Article Reprints

Li H-S, Wang S-Z, Xu H-Y, Yan X, Zhang J-Y, Lei S-Y, Li T, Hao X-Z, Zhang T, Yang G-J, et al. Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study). Cancers. 2022; 14(21):5307. https://doi.org/10.3390/cancers14215307

Li, Hong-Shuai, Shou-Zheng Wang, Hai-Yan Xu, Xiang Yan, Jin-Yao Zhang, Si-Yu Lei, Teng Li, Xue-Zhi Hao, Tao Zhang, Guang-Jian Yang, and et al. 2022. "Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)" Cancers 14, no. 21: 5307. https://doi.org/10.3390/cancers14215307

Li, H.-S., Wang, S.-Z., Xu, H.-Y., Yan, X., Zhang, J.-Y., Lei, S.-Y., Li, T., Hao, X.-Z., Zhang, T., Yang, G.-J., Zhou, L.-Q., Liu, P., Wang, Y.-Y., Hu, X.-S., Xing, P.-Y., & Wang, Y. (2022). Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study). Cancers, 14(21), 5307. https://doi.org/10.3390/cancers14215307